Member Info for Bobbler

Ahfam, take a look at Dutch IPO publication Dated 8 April2020. https://www.rvo.nl/sites/default/files/octrooiportal/2020/04/Hoofdblad_IE_1520_8_april_2020.pdf

Do a search on the PDF doc For Sareum it will take you to page 51 of 420. If you check the codes at the beginning of the doc you will see it states dates from which patent takes effect 8th April 2020. Name of invention: COMPOUNDS FOR USE IN TREATING
TYK2 KINASE MEDIATED CONDITIONS.

It’s confusing because it makes reference to previous Sareum patents. Seems a coincidence it’s in the Dutch IPO journal on the same day but with differing descriptions??? Maybe it’s late and I’m misinterpreting it?

Give me 5 minutes......... :-)

These clowns remind me of Mr Ben (50yrs + and you’ll know the cartoon). Pop in the changing room and out you come into a different world. Where do they find them???

Still have all day for SAR to release an RNS or two. Maybe a little optimistic of me :-)

TLL Pharma US patent for their Tyk2

SUMMARY OF THE INVENTION

This invention discloses novel 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives their pharmaceutically acceptable salts, solvates, hydrates and polymorphs thereof as selective Jak1 kinase inhibitors. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions associated with Jak1.

The present invention solves the problems set forth above by providing an isolated compound of Formula I:

A relevant case with regards to Patent Protection is the land mark Equivalent ruling Actavis V Eli Lilly. In view of the UK Supreme Court's judgment in Actavis v Eli Lilly, when will an 'equivalent' infringe as an immaterial variant?

…a problem of infringement is best approached by addressing two issues, each of which is to be considered through the eyes of the notional addressee of the patent in suit, i.e. the person skilled in the relevant art. Those issues are: (i) does the variant infringe any of the claims as a matter of normal interpretation; and, if not, (ii) does the variant nonetheless infringe because it varies from the invention in a way or ways which is or are immaterial? If the answer to either issue is "yes", there is an infringement; otherwise, there is not.

The patent office in the relevant Country will make a decision on novelty, prior art etc. If they decide to grant a patent and Sar feel it infringes their IP then SAR would have to apply to have the patent revoked. At this stage the risk is with the other party.

Krone. Ref Lauren Byers:

Fadec mentioned Lauren Byers is an Advisory board member for AstraZeneca. She also has a patent interest inSRA737.

Dr. Byers has received grants from Sierra Oncology; and has a patent pending on Combination of Gemcitabine + SRA737 and Anti–PD-L1.

Bottom of link: https://www.sciencedirect.com/science/article/pii/S1556086419306926

https://www.fiercepharma.com/pharma/don-t-fret-astrazeneca-investors-analysts-see-oncology-pipeline-and-alexion-as-cornerstones

Blastiod: would most likely be required :-)

9. Wombles gather en masse.
10. Wombles breading starts....even more appear
11. Clowns flock to Womble gathering, ignoring all social distancing rules.
12. Share price rockets and we all buy yachts.

Good to see Sierra had some input at least, "Travel to scientific meeting reimbursed by Sierra Oncology.; Sierra Oncology."

Charlie- you state WE are paying.....which suggests you are a shareholder. In which case if you don’t believe in SAR then surely the answer is to sell up????

Azz: I think you will find there are a number of posters who will check and research data that has been posted.

I’m sure SAR will be interested in this new compound developed in Singapore, particularly it’s relationship, if any, with its own IP.

CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01

https://www.frontiersin.org/articles/10.3389/fimmu.2020.606805/full

https://www.bbc.co.uk/news/health-56024772

Cheers :-)

Calling all LTH’s depart the board immediately. The defences have been breached, retreat to the FRV. The numpties have control of the bridge!

We’re all doomed! The end is nigh.

Or alternatively shall we just laugh at these clowns.

Clearly the lockdown has resulted in an influx of unemployed clowns. Personally I consider this a good buying signal. Thanks for signal.